Welcome to the Idaho Chapter of the American College of Cardiology
| Alina Robert, MD, FACC
Chapter President
|
| Robert Duerr, MD, FACC
Incoming Governor
|
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- SYNCHRONIZE-1: GLP-1 Survodutide Led to Significant Weight Loss in Adults With ObesitySurvodutide led to significant weight loss in adults with obesity and without diabetes, according to results from the randomized, placebo-controlled SYNCHRONIZE-1 trial published June 7 in NEJM.
- ACC Comments on 2027 IPPS Proposed RuleThe ACC submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding the fiscal year 2027 Inpatient Prospective Payment System (IPPS) proposed rule.
- CLASP IID: Residual MR and Gradient at 1 Year Post M-TEERPatients who underwent mitral transcatheter edge-to-edge repair (M-TEER) with an optimal result were more likely to have improved hemodynamics and less likely to experience major adverse events, all-cause mortality, heart failure (HF) hospitalization or reintervention at one year...
- ACC CardiaCast: The Power of the Care TeamThis episode provides a team-based overview of diagnosing and managing acute paroxysmal supraventricular tachycardia (PSVT) across care settings.
- CKD Studies Spotlight GFR Measurement, Finerenone Benefit and Rivaroxaban RiskResearch presented at the European Renal Association Congress, held June 3-6 in Glasgow, Scotland, highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment and trial results on finerenone in nondiabetic CKD and rivaroxaban in advanced CKD patients with CV risk factors.